Pharma channel feed – Endpoints News

Pharma channel feed

Lilly will test its weight loss drug directly against Novo Nordisk's Wegovy

3 years ago

Lilly divests low blood sugar rescue treatment for $500M as industry focuses on dealmaking

3 years ago

AstraZeneca, Ionis unveil full PhIII data for 'mega brand' ATTR drug

3 years ago

A ‘blistering’ start to M&A in 2023 stokes hopes of a market rebound, as insiders predict a surge in deals

3 years ago

FDA gives approval to Novartis' manufacturing site for Pluvicto

3 years ago

Serum Institute of India in talks to secure a fill-finish deal for the Oxford malaria vaccine in Ghana

3 years ago

How not to run a single-arm trial: EMA highlights more than a dozen 'biases' — and ways to mitigate them

3 years ago

Lilly, Novo Nordisk, Sanofi CEOs to face off with Bernie Sanders' health committee in May

3 years ago

Roche’s Genentech debuts first consumer effort for diabetes and age-related eye disease drug

3 years ago

SK Life Science sets up an indoor rainstorm to point to its anti-seizure drug Xcopri's full coverage

3 years ago

'We want to carry them all': Mark Cuban on why transparency is king when it comes to drug prices

3 years ago

Activist investor pushes Bayer to separate crop science, consumer health from pharma

3 years ago

Federal appeals court bars generics for Otezla until 2028

3 years ago

Bausch Health’s Salix spotlights liver disease indication for Xifaxan

3 years ago

Bipartisan PBM reforms take root in Senate Finance Committee

3 years ago

KBI Biopharma and Selexis hire J.D. Mowery as new CEO

3 years ago

Haleon’s Excedrin brand advocates no-drug approach in ‘Head Care’ campaign with celebrity dancer

3 years ago

FDA greenlights Roche's Polivy, expanding label into first-line DLBCL combo therapy

3 years ago

Bristol Myers deepens ADC pipeline in $1B+ biobuck pact with Munich startup

3 years ago

FDA's pain adcomm debates clinical trial designs for opioid post-marketing trials

3 years ago

As Eli Lilly's Mounjaro prescriptions skyrocket, analyst predicts $50B in yearly tirzepatide sales

3 years ago

In a leaked abstract, J&J's cell therapy appears to have dramatic benefits for multiple myeloma patients

3 years ago

Majority of top-selling Medicare drugs offer little added benefit to alternatives, researchers find

3 years ago

AbbVie's Qulipta adds FDA approval for chronic migraine

3 years ago

First page Previous page 127 128 129130131 132 133 Next page Last page